L-Asp is named as an intervention in 3 current clinical trials in our Canada, Australia, China, Israel and Mexico registers. 1 is recruiting patients now. All registered phases are Phase 3. The sponsor with the most trials is First Affiliated Hospital of Zhejiang University (1). The most-studied condition is ETP-ALL.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL
NCT06361329 · ClinicalTrials.gov ↗ · ETP-ALL
|
Phase 3 | Recruiting | First Affiliated Hospital of Zhejiang University | China |
|
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
NCT02101853 · ClinicalTrials.gov ↗ · Recurrent B Acute Lymphoblastic Leukemia
|
Phase 3 | Active, closed | National Cancer Institute (NCI) | Canada, Australia, Israel |
|
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
NCT02521493 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Down Syndrome, Myelodysplastic Syndrome
|
Phase 3 | Active, closed | Children's Oncology Group | Canada, Mexico, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| First Affiliated Hospital of Zhejiang University | 1 |
| National Cancer Institute (NCI) | 1 |
| Children's Oncology Group | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 2 | 0 |
| Clinical trials in Australia | 2 | 0 |
| Clinical trials in China | 1 | 1 |
| Clinical trials in Israel | 1 | 0 |
| Clinical trials in Mexico | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our Canada, Australia, China, Israel and Mexico registers name L-Asp as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 3 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
First Affiliated Hospital of Zhejiang University (1), National Cancer Institute (NCI) (1) and Children's Oncology Group (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how L-Asp works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how L-Asp works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists L-Asp (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.